VALN vs. PROK, ALEC, ALLO, HUMA, VYGR, CCCC, EDIT, TSHA, ADPT, and KYTX
Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include ProKidney (PROK), Alector (ALEC), Allogene Therapeutics (ALLO), Humacyte (HUMA), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), and Kyverna Therapeutics (KYTX). These companies are all part of the "biological products, except diagnostic" industry.
ProKidney (NASDAQ:PROK) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.
Valneva received 17 more outperform votes than ProKidney when rated by MarketBeat users. However, 66.67% of users gave ProKidney an outperform vote while only 52.27% of users gave Valneva an outperform vote.
In the previous week, ProKidney had 1 more articles in the media than Valneva. MarketBeat recorded 10 mentions for ProKidney and 9 mentions for Valneva. Valneva's average media sentiment score of 0.92 beat ProKidney's score of -0.04 indicating that ProKidney is being referred to more favorably in the media.
ProKidney has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
ProKidney currently has a consensus target price of $9.50, indicating a potential upside of 134.28%. Valneva has a consensus target price of $21.67, indicating a potential upside of 143.99%. Given ProKidney's stronger consensus rating and higher possible upside, analysts clearly believe Valneva is more favorable than ProKidney.
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 45.0% of ProKidney shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ProKidney has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.22, suggesting that its stock price is 122% more volatile than the S&P 500.
ProKidney has a net margin of 0.00% compared to ProKidney's net margin of -15.88%. Valneva's return on equity of 0.00% beat ProKidney's return on equity.
Summary
ProKidney beats Valneva on 9 of the 17 factors compared between the two stocks.
Get Valneva News Delivered to You Automatically
Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
